<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991741</url>
  </required_header>
  <id_info>
    <org_study_id>160710</org_study_id>
    <nct_id>NCT03991741</nct_id>
  </id_info>
  <brief_title>Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors</brief_title>
  <official_title>Phase I Trial of Lymphodepletion Followed by Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregory Daniels</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunotherapy Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether special tumor fighting cells that is taken from participants' tumors and&#xD;
      grown in the laboratory and then given back to the participant will fight the participant's&#xD;
      cancer when their immune system is suppressed from attacking these special tumor fighting&#xD;
      cells. This is called transfer of autologous (they came from you) tumor infiltrating&#xD;
      lymphocytes (the cells that have been grown in the laboratory. Participants getting these&#xD;
      cell infusions will also be treated with interleukin-2 (IL-2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment related Adverse Events</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Locally Advanced Refractory/Recurrent Melanoma</condition>
  <condition>Metastatic Head and Neck Cancer</condition>
  <condition>Locally Advanced Refractory/Recurrent Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>head and neck cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Tumor Infiltrating Lymphocytes</intervention_name>
    <description>Autologous TILs</description>
    <arm_group_label>head and neck cancer</arm_group_label>
    <arm_group_label>melanoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Interleukin 2</intervention_name>
    <description>720,000 IU/kg every 8 hours for up to 15 doses</description>
    <arm_group_label>head and neck cancer</arm_group_label>
    <arm_group_label>melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologically confirmed diagnosis of head and neck squamous cell&#xD;
             carcinoma OR metastatic cutaneous or mucosal melanoma measurable per RECIST.&#xD;
&#xD;
          -  Progressive squamous cell cancer of the head and neck or metastatic melanoma since&#xD;
             prior systemic treatment and who are:&#xD;
&#xD;
               1. Not candidates for known curative intent therapy.&#xD;
&#xD;
               2. Progressed following at least one prior systemic therapy.&#xD;
&#xD;
               3. Have advanced melanoma unresectable stage III or stage IV&#xD;
&#xD;
               4. Have advanced head and neck recurrent or metastatic disease&#xD;
&#xD;
          -  Have no more than 3 brain metastases. Note: If lesions are symptomatic or â‰¥ 1 cm each,&#xD;
             these lesions must have been treated and stable for 3 months for the patient to be&#xD;
             eligible.&#xD;
&#xD;
          -  Life expectancy of greater than 3 months.&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
          -  Seronegative for HIV antibody.&#xD;
&#xD;
          -  Seronegative for Hepatitis B antigen, or Hepatitis C antibody or antigen.&#xD;
&#xD;
          -  More than four weeks has elapsed since the patient received any prior systemic therapy&#xD;
             at the time of enrollment.&#xD;
&#xD;
          -  Patient has stable or progressing disease after at least one prior treatment.&#xD;
&#xD;
          -  Six weeks or more have elapsed since the patient received any prior anti-CTLA4&#xD;
             antibody therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently using investigational agents.&#xD;
&#xD;
          -  Had prior cell transfer therapy which included a non-myeloablative or myeloablative&#xD;
             chemotherapy regimen.&#xD;
&#xD;
          -  Patient is a female of child-bearing potential who is pregnant or breastfeeding&#xD;
&#xD;
          -  Patient requires immune suppressive therapy including but not limited to greater than&#xD;
             physiologic steroid replacement.&#xD;
&#xD;
          -  Active systemic infections, coagulation disorders or other active major medical&#xD;
             illnesses of the cardiovascular, respiratory or immune system, as evidenced by a&#xD;
             positive stress thallium or comparable test, myocardial infarction, cardiac&#xD;
             arrhythmias, obstructive or restrictive pulmonary disease.&#xD;
&#xD;
          -  Patient has any form of primary immunodeficiency (such as Severe Combined&#xD;
             Immunodeficiency Disease and AIDS).&#xD;
&#xD;
          -  Patient has opportunistic infections.&#xD;
&#xD;
          -  Patient has a history of coronary revascularization or ischemic symptoms.&#xD;
&#xD;
          -  Patients with clinically significant atrial and/or ventricular arrhythmias including&#xD;
             but not limited to: atrial fibrillation, ventricular tachycardia, second or third&#xD;
             degree heart block.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Daniels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Gregory Daniels</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>metastatic</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>adoptive cell therapy</keyword>
  <keyword>autologous</keyword>
  <keyword>locally advanced refractory/recurrent melanoma</keyword>
  <keyword>locally advanced refractory/recurrent head and neck cancer</keyword>
  <keyword>IL-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

